Roberts et al., "Rational Design of Peptide-Based Proteinase Inhibitors", Science, 248, 358 (1900). |
Erickson et al., "Design Activity and 2.8A Crystall Structure of C.sub.2 Symmetric Inhibitor Complexed to HIV-1 Protease", Science 249, 527 (1990). |
Pearl et al., "Sequence specificity of Retroviral Protease"Nature, vol. 328, No. 6130, Aug. 6-12, 1987, p. 482. |
Martin, Drugs of the Future, 1991 16(3), 210-212. |
Meek et al., "Inhibition of HIV-1 Protease in Infected T-lymphocytes by Synthetic Peptide Analogues", Nature, 343, 90 (1990). |
McQuade et al., "A Synthetic HIV-1 Protease Inhibitor with Antiviral Activity Arrests HIV-Like Particle Maturation", Science, 274, 454-456 (1990). |
D.H. Rich and V.J. Hunby; Dept. Struct. Funct. Proc. Am. Peptide Inhibitors of Protease Sym. 8th ed., pp. 511-520 (1983). |
Rosenberg et al., J. Med. Chem., 30, 1224-1228 (1987). |
Waldholz, "merck Joins Roche . . . ", The Wall Street Journal, 17 Jul. 1995, p. B3. |
Becker, International Dictionary of Medicine and Biology, p. 2316, 1986. |
Ghosh, "Cyclic Sulfone-3-Carboxamides . . . ", Bioorganic & Medicinal Chemistry Letters, vol. 5, No. 1, pp. 83-88, 1995. |
Ho, "Rapid Turnover of Plasma . . . ", Nature, vol. 373, pp. 123-126, Jan. 1995. |
Waldholz, "Merck's Elation . . .", The Wall Street Journal, 17 Jul. 1995, p. B3. |
Wel, "Viral Dynamics in Human . . . ", Nature, vol. 373, pp. 117-122, Jan. 1995. |